Oncology Drug Articles & Analysis
10 articles found
Many oncology drugs have been abandoned by pharmaceutical companies due to poor performance in phase I, II, or III clinical trials. These drugs represent untapped potential treatments for indications outside of those initially investigated. With research and development costs for a single new drug estimated between $2–3 ...
This article explores the mechanisms, benefits, challenges, and future prospects of PEGylation in drug development. Mechanism of PEGylation PEGylation involves the covalent or non-covalent attachment of PEG—a synthetic, hydrophilic polymer—to a drug molecule. ...
Oncology drug development makes up almost half of the annual R&D expenditure of biopharmaceutical companies. Only 10% of drugs advanced to the clinical stage are successfully brought to market, with half of all failures attributed to lack of clinical efficacy. ...
The services tend to accelerate the discovery and optimization of molecule drugs with a strict quality control system. Small molecule drugs are characterized by their low molecular weight and simple chemical structures. ...
Antibody-drug conjugates (ADCs) represent a rapidly developing field within pharmaceutical biotechnology. ...
To discover novel druggable targets for cancers carrying co-mutations in Ras and p53, we performed arrayed, kinome focused siRNA and oncology drug phenotypic screening utilizing a set of syngeneic Ras mutant squamous cell carcinoma (SCC) cell lines that also carried co-mutations in selected p53 pathway genes. These cell lines were derived from SCCs from ...
Planning and executing oncology trials can quickly become complex, mainly for the following reasons: Budgets: Phase 2 and 3 oncology trial budgets are nearly double those of non-oncology trials, per patient enrolled. ...
Introduction “Our priority is to provide our customers with the high purity water and steam that is critical to the development and manufacturing of life-saving medications now and for future generations.” —George Gsell, MECO President Nexus Pharmaceuticals, maker of difficult-to-manufacture, high quality, FDA-approved specialty and generic drugs, is opening a $250 million, ...
In 2020, the company did much the same, announcing a drug candidate with Sumitomo Dainippon Pharma in Osaka, Japan, then later raising $100 millionin Series C funding. That drug, a selective serotonin reuptake inhibitor (SSRI) designed to treat obsessive compulsive disorder (OCD), and the oncology drug are the first two molecules ...
ByIktos
Name: Imran Ahmed Job Title: Senior Research Scientist Company: Fresenius Kabi Oncology Ltd., Gurgoan, India Imran Ahmed, Senior Research Scientist, Fresenius Kabi Oncology Ltd Fresenius Kabi Oncology, performing with Precision Fresenius Kabi Oncology Ltd. primarily operates in the field of research and development, as ...